Dec'22 | Dec'23 | |
---|---|---|
P/EBITDA LTM | (0.0x) | (41.3x) |
Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.2 | 0.4 |
% margin | (0.0) 0.0% | (0.0) 0.0% | (0.2) 0.0% | (0.4) 0.0% |
Operating Expenses | 5.7 | 9.8 | 12.8 | 31.7 |
Research & Development Expenses (R&D) | 3.7 | 7.4 | 8.9 | 24.8 |
Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 4.0 | 6.8 |
% margin | (5.7) 0.0% | (9.8) 0.0% | (12.8) 0.0% | (31.7) 0.0% |
Interest Income | 0.0 | 0.0 | 0.0 | 0.1 |
Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 |
Pre-tax Income | (5.8) | (9.7) | (12.6) | (31.6) |
% effective tax rate | 0.0 (0.0%) | 0.1 (1.3%) | (0.2) 1.4% | 0.0 (0.0%) |
% margin | (5.8) 0.0% | (9.8) 0.0% | (12.5) 0.0% | (31.6) 0.0% |
EPS | (0.24) | (0.41) | (0.62) | (1.19) |
Diluted EPS | (0.24) | (0.41) | (0.62) | (1.19) |
% margin | (5.7) 0.0% | (9.6) 0.0% | (12.4) 0.0% | (31.5) 0.0% |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is (38.5x), based on the financial report for Sep 27, 2024 (Q3’2024). The average annual P/EBITDA LTM for Belite Bio, Inc have been (28.4x) over the past three years, and (21.3x) over the past five years.
As of today, Belite Bio, Inc's P/EBITDA LTM is (38.5x), which is lower than industry median of (1.5x). It indicates that Belite Bio, Inc's P/EBITDA LTM is Good.